GlassScriptPhysician profile
Jeffrey N Greer
NPI 1386640027
$9,889.74
in general payments reported to CMS, 2019-2025
50 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $1,441 · 2021: $1,535 · 2022: $1,457 · 2023: $1,011 · 2024: $1,704 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,859.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,232.34 | 2019-2025 | |
| Lilly USA, LLC | $780.09 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $755.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $619.22 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $578.54 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.58 | 2019-2025 | Jardiance |
| Pfizer INC. | $444.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $390.99 | 2019-2025 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.41 | 2020-2025 | Xifaxan, Trulance |
| Allergan, INC. | $305.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $272.32 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $236.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $213.53 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Amarin Pharma, INC. | $175.13 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $148.36 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.